home / stock / allr / allr news

ALLR News and Press, Allarity Therapeutics Inc. From 05/27/22

Stock Information
Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ
Website: allarity.com
Menu
ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLR - Avadel, PMV Pharmaceuticals top healthcare gainers; Iovance, SpringWorks lead losers' pack

Gainers: Avadel Pharmaceuticals AVDL +61%. PMV Pharmaceuticals PMVP +25%. Alpha Tau Medical (DRTS) +18%. SIGA Technologies SIGA +18%. Allarity Therapeutics (ALLR) +17%. Losers: Iovance Biotherapeutics (IOVA) -54%. SpringWorks Therapeutics SWTX...
ALLR - Allarity, Better Therapeutics top healthcare gainers; INmune Bio, Liquidia lead losers' pack

Gainers: Allarity Therapeutics (ALLR) +13%. Better Therapeutics (BTTX) +19%. GeoVax Labs GOVX +10%. Insulet PODD +7%. MDxHealth (MDXH) +5%. Losers: INmune Bio (INMB) -29%. Liquidia (LQDA) -21%. TherapeuticsMD (TXMD) -19%. Aethlon Medical (AEMD) -14%.&#x...

ALLR - GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers' pack

Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides...

ALLR - NNVC, BEST and PYR among mid-day movers

Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...
ALLR - Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Cambridge, MA U.S.A. ( May 1 8 , 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corpor...

ALLR - Allarity Therapeutics reports Q4 results

Allarity Therapeutics press release (NASDAQ:ALLR): Q4 net loss was $16.8M for the three months ended December 31, 2021, and $26.6M for the full year 2021, compared to $1.7M and $6.6M for comparable periods in 2020, respectively. As of December 31, 2021, Allarity’s cash was $19.6M,...

ALLR - Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Cambridge, MA U.S.A. ( May 16 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostic...
ALLR - Allarity Therapeutics says no longer in compliance with Nasdaq listing rules

Allarity Therapeutics (NASDAQ:ALLR) on Friday said it got a Nasdaq notice on April 20 that it was no longer in compliance with listing rules due to delay in its 10-K filing for the fiscal year ended Dec. 31, 2021. ALLR has 60 days to submit to Nasdaq a plan to regain compliance. If Nasdaq acc...

ALLR - Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Cambridge, MA U.S.A. ( April 22 , 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® co...

ALLR - Allarity Therapeutics Provides Update on Dovitinib Program

FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s N...
Previous 10 Next 10